268. Nakajo-Nishimura syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trial : 0 / Drug : 0 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
Nakajo-Nishimura syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 268 | Nakajo-Nishimura syndrome | - |
| 325 | Hereditary autoinflammatory syndrome | 2.000 |
| 46 | Malignant rheumatoid arthritis | 2.000 |
| 49 | Systemic lupus erythematosus | 2.000 |
| 51 | Scleroderma | 2.000 |
| 65 | Primary immunodeficiency | 2.000 |
| 84 | Sarcoidosis | 2.000 |
| 96 | Crohn disease | 2.000 |
| 256 | Muscle glycogenosis | 2.000 |
| 53 | Sjogren syndrome | 2.000 |
| 271 | Ankylosing spondylitis | 2.000 |
| 162 | Pemphigoid | 2.000 |
| 228 | Bronchiolitis obliterans | 2.000 |
| 265 | Lipodystrophy | 2.000 |
| 93 | Primary biliary cholangitis | 2.000 |
| 50 | Dermatomyositis | 2.000 |
| 107 | Juvenile idiopathic arthritis | 2.000 |
| 97 | Ulcerative colitis | 2.000 |
| 40 | Takayasu arteritis | 2.000 |
| 41 | Giant cell arteritis | 2.000 |
| 269 | Pyogenic arthritis | 2.000 |
| 11 | Myasthenia gravis | 2.000 |
| 44 | Wegener granulomatosis | 2.000 |